---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001513"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:29:01.132827+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023

## Summary
- Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.
- Cash and cash equivalents at Dec 31, 2024 were $4.6M, up from $3.4M at year-end 2023.
- Cash used in operations for FY2024 was $9.6M, compared to $15.8M in 2023.
- Clinical progress: AgenT-797 Phase 2 gastric cancer trial enrolling; ARDS data showed ~80% survival in VV ECMO patients.
- Raised $5.8M in private financing in 2024; collaboration with Autonomous Therapeutics for RNA-iNKT therapies.

## SEC filing metadata
- accession: 0001171843-25-001513
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/0001171843-25-001513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/f8k_031825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001513
- JSON: https://secwatch.observer/filing/0001171843-25-001513.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.